Onconova to Present at the Spring 2021 Oncology Investor Conference
March 29 2021 - 8:00AM
Onconova Therapeutics, Inc. (NASDAQ: ONTX)
(“Onconova”), a clinical-stage biopharmaceutical company
focused on discovering and developing novel products for patients
with cancer, today announced that Steven Fruchtman, M.D., President
and Chief Executive Officer, will present a Company overview and
hold one-on-one meetings during the Spring 2021 Oncology Investor
Conference, sponsored by the National Foundation for Cancer
Research.
Event: Spring 2021
Oncology Investor ConferenceDate: The virtual
conference will take place March 29 to April 2,
2021Onconova Presentation: Thursday, April 1,
2021 at 11:50 a.m. Eastern timeConference Registration
Link:
https://www.oncologyinvestorconference.com/register
A webcast of Dr. Fruchtman’s presentation will
be available on the Company’s website at
https://investor.onconova.com/events-and-presentations beginning
Friday, April 2nd.
About Onconova Therapeutics,
Inc.
Onconova Therapeutics is a clinical-stage
biopharmaceutical company focused on discovering and developing
novel therapies for patients with cancer. The Company has
proprietary targeted anti-cancer agents designed to disrupt
specific cellular pathways that are important for cancer cell
proliferation.
Onconova’s novel, proprietary multi-kinase
inhibitor ON 123300 is planned to begin a dose-escalation and
expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation
and expansion Phase 1 trial is currently underway in China.
Onconova’s product candidate oral rigosertib is currently in a
dose-escalation and expansion Phase 1 investigator-initiated study
targeting patients with KRAS+ lung adenocarcinoma in combination
with nivolumab. In addition, Onconova continues to conduct
preclinical work investigating rigosertib in COVID-19. For more
information, please visit www.onconova.com.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, and involve risks and uncertainties.
These statements relate to Onconova’s expectations regarding the
registered direct offering, its patents and clinical development
plans including patient enrollment timelines and indications for
its product candidates. Onconova has attempted to identify
forward-looking statements by terminology including "believes,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should," "approximately" or other words
that convey uncertainty of future events or outcomes. Although
Onconova believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including the success and
timing of Onconova's clinical trials and regulatory agency and
institutional review board approvals of protocols, Onconova’s
ability to continue as a going concern, the need for additional
financing, Onconova’s collaborations, market conditions and those
discussed under the heading "Risk Factors" in Onconova's most
recent Annual Report on Form 10-K and quarterly reports on Form
10-Q. Any forward-looking statements contained in this release
speak only as of its date. Onconova undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Company Contact:Avi
OlerOnconova Therapeutics, Inc.267-759-3680
ir@onconova.ushttps://www.onconova.com/contact/
Investor Contact:LHA Investor
Relations Kim Sutton Golodetz212-838-3777kgolodetz@lhai.com
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024